PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment
J Thouvenin1, C Van Marcke2, L Decoster3
1Hospices Civils de Lyon, Medical Oncology, Lyon, France; Institut Jules Bordet, Medical Oncology Clinic, Brussels, Belgium.
Abstract:
PRECISION is an initiative from the Belgian Society of Medical Oncology (BSMO) in collaboration with several stakeholders, encompassing four programs that aim to boost genomic and clinical knowledge with the ultimate goal to offer patients with metastatic solid tumors molecularly guided treatments. The PRECISION 1 study has led to the creation of a clinico-genomic database. The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) and GeNeo studies will increase the number of patients with advanced cancer that have comprehensive genotyping of their cancer. The PRECISION 2 project consists of investigator-initiated phase II studies aiming to provide access to a targeted drug for patients whose tumors harbor actionable mutations in case the matched drug is not available through reimbursement or clinical trials in Belgium.
Insights
The PRECISION initiative aims to improve molecularly guided treatments for metastatic solid tumors. It enhances genomic and clinical knowledge through studies like PRECISION 1 and PRECISION 2, benefiting advanced cancer patients.
Area of Science:
- Oncology
- Genomics
- Translational Research
Background:
- The PRECISION initiative by the Belgian Society of Medical Oncology (BSMO) seeks to advance cancer care.
- Existing gaps in genomic and clinical data hinder personalized treatment for metastatic solid tumors.
Purpose of the Study:
- To establish a comprehensive clinico-genomic database through the PRECISION 1 study.
- To expand molecular profiling in advanced cancer patients via the BALLETT and GeNeo studies.
- To facilitate access to targeted therapies for patients with actionable mutations through PRECISION 2 investigator-initiated trials.
Main Methods:
- Creation of a clinico-genomic database.
- Comprehensive tumor genotyping for advanced cancer patients.
- Phase II investigator-initiated studies for targeted drug access.
Main Results:
- Established a valuable clinico-genomic database from PRECISION 1.
- Increased the number of advanced cancer patients undergoing comprehensive genotyping.
- Provided access to targeted drugs for patients with specific actionable mutations.
Conclusions:
- The PRECISION initiative significantly enhances genomic and clinical knowledge in oncology.
- It facilitates molecularly guided treatments for patients with metastatic solid tumors.
- PRECISION improves access to novel targeted therapies for Belgian cancer patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...